Self-Emulsifying Drug Delivery Systems (SEDDS): An Innovative Approach to Enhance Oral Bioavailability of Poorly Soluble Drugs

Abstract

Poor aqueous solubility remains a significant barrier in oral drug delivery, often resulting in suboptimal bioavailability and therapeutic efficacy. Self-Emulsifying Drug Delivery Systems (SEDDS) offer a novel and effective approach to address this challenge. These systems are isotropic mixtures of oils, surfactants, and co-surfactants that spontaneously form fine oil-in-water emulsions upon mild agitation in gastrointestinal fluids, thereby enhancing drug solubilization and absorption. This review explores the fundamental principles and formulation strategies of SEDDS, including their transition from liquid to solid dosage forms, which improves stability and patient compliance. Key characterization techniques such as droplet size analysis, zeta potential measurement, and in vitro dissolution studies are discussed to evaluate formulation performance. Applications of SEDDS span a wide range of therapeutic areas, including immunosuppressants, anticancer agents, and antiviral drugs. Emerging innovations such as super saturable SEDDS, hybrid systems, and 3D-printed tablets are expanding the scope of this technology. Despite certain limitations like excipient toxicity and drug loading constraints, SEDDS continue to evolve as a versatile platform for enhancing oral bioavailability of poorly soluble drugs. Future research should focus on scalable manufacturing, regulatory harmonization, and patient-centric design to fully realize the potential of SEDDS in modern pharmaceutical development.

Keywords

Introduction

Figure 1. Schematic representation of a SEDDS formulation showing oil, surfactant, and co-surfactant components forming nano/micro-emulsion droplets upon contact with GI fluids.

Figure 2. Pseudo-ternary phase diagram showing emulsification region for different oil–surfactant–co-surfactant ratios.

Figure 3. Flowchart of solidification techniques for converting liquid SEDDS to solid dosage forms.

Challenges:

• Limited drug loading for highly lipophilic drugs (6,7)
• Stability issues in liquid form (8)
• Need for careful excipient selection to avoid toxicity (9,10)

Emerging Trends:

• Supersaturable SEDDS (Su-SEDDS): Incorporating precipitation inhibitors to maintain drug in supersaturated state (12).
• Hybrid SEDDS: Combining with polymeric nanoparticles for dual benefits (13).
• 3D-printed SEDDS tablets: Personalized dosing and release profiles (1).

5. CONCLUSION

SEDDS represent a versatile and effective strategy for improving the oral delivery of poorly soluble drugs. Advances in formulation science, particularly in solidification techniques and hybrid systems, are expanding their applicability. Future research should focus on patient-centric designs, scalable manufacturing, and regulatory harmonization.

REFERENCE

1. Uttreja P, Karnik I, Youssef AAA, et al. Self-Emulsifying Drug Delivery Systems (SEDDS): Transition from Liquid to Solid—A Comprehensive Review. Pharmaceutics. 2025;17(1):63.
2. Pouton CW. Formulation of poorly water-soluble drugs for oral administration. Eur J Pharm Sci. 2006;29(3-4):278–287.
3. Porter CJH, Trevaskis NL, Charman WN. Lipid-based formulations as enabling strategies. Adv Drug Deliv Rev. 2007;60(6):673–691.
4. Singh B, Bandopadhyay S, Kapil R, Singh R, Katare OP. Self-emulsifying drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2009;26(5):427–521.
5. Tang B, Cheng G, Gu JC, Xu CH. Development of solid self-emulsifying drug delivery systems. Drug Discov Today. 2008;13(13-14):606–612.
6. Kommuru TR, Gurley B, Khan MA, Reddy IK. SEDDS of coenzyme Q10. Int J Pharm. 2001;212(2):233–246.
7. Mohsin K, Long MA, Pouton CW. Design of lipid formulations. J Pharm Pharmacol. 2009;61(10):1241–1252.
8. Jaiswal P, Aggarwal G, Harikumar SL. Development of SMEDDS and solid-SMEDDS of telmisartan. Int J Pharm Investig. 2014;4(4):195–206.
9. Balakrishnan P, Lee BJ, Oh DH, et al. Enhanced oral bioavailability of coenzyme Q10. Int J Pharm. 2009;374(1-2):66–72.
10. Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems. Nanomedicine. 2010;5(10):1595–1616.
11. Constantinides PP. Lipid microemulsions for improving drug dissolution. Pharm Res. 1995;12(11):1561–1572.
12. Gao P, Morozowich W. Supersaturatable SEDDS. Expert Opin Drug Deliv. 2006;3(1):97–110.
13. Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design of halofantrine. Int J Pharm. 1998;167(1-2):155–164.
14. Hauss DJ, Fogal SE, Ficorilli JV, et al. Lipid-based delivery systems for LTB4 inhibitor. J Pharm Sci. 1998;87(2):164–169.
15. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66(2):227–243.
16. Patel AR, Vavia PR. SMEDDS containing fenofibrate. AAPS J. 2007;9(3): E344–E352.